A Single Ascending Dose, Open Label, Exploratory Study of OTL-038 for the Intra-operative Imaging of Folate Receptor Alpha Positive Ovarian, Renal Cell and Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 20 May 2019
Price : $35 *
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Endometrial cancer; Ovarian cancer; Renal cancer
- Focus Adverse reactions; Diagnostic use; Pharmacokinetics
- Sponsors On Target Laboratories
- 18 May 2019 Status changed from recruiting to completed.
- 18 May 2019 Planned number of patients changed from 18 to 66.
- 16 Sep 2014 New trial record